. 2017 Jan 19;13(2):311–320. doi: 10.5114/aoms.2017.65240

Table VI.

Lipid profiles for patients with MI in the dynamics of hospital stay (Me: Q1; Q3)

Variable	Control (n = 33)	Patients without type 2 diabetes (n = 171)		Patients with first diagnosed type 2 diabetes (n = 29)
Variable	Control (n = 33)	1^st day	12^th day	1^st day	12^th day
TC [mmol/l]	4.30 (3.50; 6.10)	5.55 (4.40; 6.50)^a	5.40 (4.40; 6.40)	5.50 (4.20; 7.00)^a	5.70 (4.90; 6.10)
TAG [mmol/l]	1.13 (0.78; 1.23)	1.60 (1.15; 2.17)	2.05 (1.43; 2.70)^b	2.75 (2.01; 2.87)^a^,^c	2.57 (1.44; 3.22)
HDL-C [mmol/l]	1.31 (1.02; 1.72)	1.02 (0.83; 1.16)	1.02 (0.84; 1.16)	0.78 (0.58; 0.94)^a^,^c	0.84 (0.58; 1.13)
LDL-C [mmol/l]	2.03 (1.51; 2.55)	2.74 (2.09; 3.41)	2.62 (1.95; 3.35)	1.98 (1.86; 3.10)	2.41 (0.82; 2.56)
VLDL-C [mmol/l]	0.44 (0.33; 0.53)	0.73 (0.52; 0.98)	0.93 (0.65; 1.23)^b	1.25 (0.91; 1.30)^a^,^c	1.17 (0.65; 1.46)
apo B [g/l]	1.02 (0.76; 1.25)	1.18 (0.95; 1.39)	1.36 (1.08; 1.64) ^b	1.51 (1.19; 1.72)^a	1.38 (1.21; 1.84)
apo A1 [g/l]	1.43 (1.29; 1.73)	1.27 (1.11; 1.42)	1.38 (1.18; 1.74)^b	1.13 (1.06; 1.22)^a	1.15 (1.01; 1.63)
apo B/apo A1	0.71 (0.59; 1.00)	0.90 (0.75; 1.12)	0.92 (0.73; 1.16)	1.25 (1.12; 1.62)^a^,^c	1.05 (0.83; 1.60)
FFA [μmol/l]	0.20 (0.10; 1.10)	1.63 (1.24; 2.00)^a	0.54 (0.41; 0.73)^b	1.91 (1.62; 2.05)^a	0.90 (0.59; 0.99)^b^,^c

Statistically significant difference compared with the control group (p < 0.05)

reliable differences in indicators at day 1 and day 12 (p < 0.05)

reliable differences between parameters of the study groups (p < 0.05). TC – total cholesterol, TAG – triglyceride, HDL-C – high-density lipoprotein cholesterol, LDL-C – low-density lipoprotein cholesterol, VLDL-C – very-low-density lipoprotein cholesterol, apo B – apolipoprotein B, apo A1 – apolipoprotein A1.